1/12
08:27 am
caba
Cabaletta Bio Announces 2026 Strategic Priorities [Yahoo! Finance]
Medium
Report
Cabaletta Bio Announces 2026 Strategic Priorities [Yahoo! Finance]
1/12
08:00 am
caba
Cabaletta Bio Announces 2026 Strategic Priorities
Medium
Report
Cabaletta Bio Announces 2026 Strategic Priorities
1/12
07:30 am
caba
IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms
Medium
Report
IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms
12/15
07:15 am
caba
Is Cabaletta Bio (NASDAQ:CABA) In A Good Position To Invest In Growth? [Yahoo! Finance]
Low
Report
Is Cabaletta Bio (NASDAQ:CABA) In A Good Position To Invest In Growth? [Yahoo! Finance]
11/10
07:59 am
caba
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
11/10
07:55 am
caba
Cabaletta Bio GAAP EPS of -$0.44 beats by $0.04 [Seeking Alpha]
Medium
Report
Cabaletta Bio GAAP EPS of -$0.44 beats by $0.04 [Seeking Alpha]
11/10
07:30 am
caba
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
11/4
07:01 pm
caba
Cabaletta Bio (CABA): Assessing Valuation After Promising Clinical Trial Results and Growing Investor Interest [Yahoo! Finance]
Low
Report
Cabaletta Bio (CABA): Assessing Valuation After Promising Clinical Trial Results and Growing Investor Interest [Yahoo! Finance]
11/4
08:00 am
caba
Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December
Medium
Report
Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December
10/31
09:52 am
caba
Cabaletta Bio (NASDAQ:CABA) had its price target raised by analysts at Cantor Fitzgerald from $15.00 to $30.00. They now have an "overweight" rating on the stock.
High
Report
Cabaletta Bio (NASDAQ:CABA) had its price target raised by analysts at Cantor Fitzgerald from $15.00 to $30.00. They now have an "overweight" rating on the stock.
10/27
07:00 am
caba
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025
High
Report
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025